Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endosome. Note=Accumulates on perinuclear endosomes. |
Domain | - |
Function |
May play a role in regulating vesicuar trafficking in cells. |
Biological Process |
GO:0007034 vacuolar transport GO:0016197 endosomal transport |
Molecular Function | - |
Cellular Component |
GO:0005798 Golgi-associated vesicle GO:0012510 trans-Golgi network transport vesicle membrane GO:0030133 transport vesicle GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0030140 trans-Golgi network transport vesicle GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030660 Golgi-associated vesicle membrane GO:0030662 coated vesicle membrane GO:0030665 clathrin-coated vesicle membrane |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between RASSF9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of RASSF9 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of RASSF9 in various data sets.
|
Points in the above scatter plot represent the mutation difference of RASSF9 in various data sets.
|
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RASSF9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RASSF9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RASSF9. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RASSF9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of RASSF9 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between RASSF9 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | RASSF9 |
Name | Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 |
Aliases | P-CIP1; PAMCI; peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor; PCIP1; PAM COOH-termi ...... |
Chromosomal Location | 12q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting RASSF9 collected from DrugBank database. |
There is no record. |